Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) was the recipient of a large decline in short interest in the month of February. As of February 28th, there was short interest totalling 2,600,000 shares, a decline of 27.2% from the February 13th total of 3,570,000 shares. Based on an average daily volume of 562,300 shares, the short-interest ratio is currently 4.6 days. Currently, 13.1% of the company's shares are sold short.
Analyst Upgrades and Downgrades
A number of research analysts recently issued reports on ENTA shares. JMP Securities reiterated a "market outperform" rating and set a $21.00 target price on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 11th. Robert W. Baird decreased their price target on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an "outperform" rating for the company in a research note on Tuesday, November 26th. StockNews.com upgraded shares of Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Wednesday, February 19th. Finally, HC Wainwright reiterated a "buy" rating and issued a $18.00 target price on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 11th. One analyst has rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Enanta Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $17.25.
Check Out Our Latest Stock Report on Enanta Pharmaceuticals
Insider Transactions at Enanta Pharmaceuticals
In related news, CEO Jay R. Luly bought 45,000 shares of the company's stock in a transaction that occurred on Wednesday, February 12th. The shares were bought at an average price of $5.69 per share, for a total transaction of $256,050.00. Following the transaction, the chief executive officer now directly owns 846,638 shares of the company's stock, valued at approximately $4,817,370.22. The trade was a 5.61 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 13.89% of the company's stock.
Hedge Funds Weigh In On Enanta Pharmaceuticals
Several institutional investors have recently added to or reduced their stakes in the stock. US Bancorp DE lifted its holdings in Enanta Pharmaceuticals by 4,933.7% during the third quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company's stock valued at $45,000 after purchasing an additional 4,243 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Enanta Pharmaceuticals in the fourth quarter worth about $26,000. Tower Research Capital LLC TRC lifted its holdings in shares of Enanta Pharmaceuticals by 46.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company's stock worth $41,000 after buying an additional 2,274 shares in the last quarter. Intech Investment Management LLC purchased a new stake in shares of Enanta Pharmaceuticals in the fourth quarter worth about $58,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of Enanta Pharmaceuticals in the fourth quarter worth about $66,000. Institutional investors own 94.99% of the company's stock.
Enanta Pharmaceuticals Stock Performance
ENTA remained flat at $6.44 during trading on Thursday. 102,322 shares of the company traded hands, compared to its average volume of 277,579. The firm has a market capitalization of $137.38 million, a price-to-earnings ratio of -1.30 and a beta of 0.48. The firm's 50 day moving average price is $6.26 and its two-hundred day moving average price is $8.51. Enanta Pharmaceuticals has a one year low of $4.71 and a one year high of $17.80.
Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last posted its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.05) earnings per share for the quarter, beating the consensus estimate of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative net margin of 157.57% and a negative return on equity of 75.53%. On average, research analysts anticipate that Enanta Pharmaceuticals will post -4.65 earnings per share for the current fiscal year.
About Enanta Pharmaceuticals
(
Get Free Report)
Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.
Featured Stories
Before you consider Enanta Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enanta Pharmaceuticals wasn't on the list.
While Enanta Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
